A5076738875- Cancer Immunotherapy and Biomarkers
- Angiogenesis and VEGF in Cancer
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Cancer, Hypoxia, and Metabolism
- Immunotherapy and Immune Responses
- Hepatocellular Carcinoma Treatment and Prognosis
- PARP inhibition in cancer therapy
- Cancer Cells and Metastasis
- Cancer, Stress, Anesthesia, and Immune Response
- Lipid metabolism and disorders
- Immune Cell Function and Interaction
- Cancer Genomics and Diagnostics
- Cutaneous lymphoproliferative disorders research
- Estrogen and related hormone effects
- Lung Cancer Treatments and Mutations
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Silicon Carbide Semiconductor Technologies
- Inflammatory Biomarkers in Disease Prognosis
- Immune cells in cancer
- T-cell and B-cell Immunology
- Head and Neck Cancer Studies
- Vascular Tumors and Angiosarcomas
- Virus-based gene therapy research
Dana-Farber Cancer Institute
2016-2021
Brigham and Women's Hospital
2017-2020
Harvard University
2016-2020
Axicabtagene ciloleucel (axi-cel) was approved by the Food and Drug Administration for relapsed aggressive B-cell non-Hodgkin lymphoma in part on basis of durable remission rates approximately 40% a clinical trial population. Whether this efficacy, toxicity, would be consistent postcommercial setting, with relaxed eligibility criteria bridging therapy, is unknown. This study describes efficacy safety correlates outcomes setting.
Immune checkpoint therapies targeting CTLA-4 and PD-1 have proven effective in cancer treatment. However, the identification of biomarkers for predicting clinical outcomes mechanisms to overcome resistance remain as critical needs. Angiogenesis is increasingly appreciated an immune modulator with potential combinatorial use blockade. Angiopoietin-2 (ANGPT2) target patients involved anti-VEGF treatment monoclonal antibody bevacizumab. We investigated predictive prognostic value circulating...
Hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer is associated with low levels of stromal tumor-infiltrating lymphocytes (sTIL) and PD-L1, demonstrates poor responses to checkpoint inhibitor therapy. Evaluating the effect standard chemotherapy on immune microenvironment may suggest new opportunities for immunotherapy-based approaches treating HR+/HER2- tumors.HR+/HER2- tumors were analyzed before after neoadjuvant chemotherapy. sTIL assessed histologically; CD8+ cells, CD68+...
Mechanisms of chimeric antigen receptor (CAR) T cell-mediated antitumor immunity and toxicity remain poorly characterized because few studies examine the intact tumor microenvironment (TME) following CAR cell infusion. Axicabtagene ciloleucel is an autologous anti-CD19 therapy approved for patients with large B lymphoma. We devised multiplex immunostaining ISH assays to interrogate cells other immune infiltrates in biopsies diffuse lymphoma axicabtagene found that a majority intratumoral...
A single dose of bevacizumab reduced the density angiopoietin-2-positive vessels while improving infiltration CD4+ T and CD8+ cells, mature dendritic cells in patients with primary triple-negative breast cancer. Our findings provide a rationale for including during neoadjuvant treatment to enhance efficacy immune checkpoint blockers this disease.
Introduction: Natural Killer cells (NKC) play an important role in tumor immune-surveillance. AFM13 is a CD30/CD16A targeting high affinity bispecific tetravalent antibody that engages and activates NKC. This study evaluates clinical immunological activity. It examines the immunologic changes peripheral blood (PB) as function of dose method administration over time. Methods: Subjects with relapsed or refractory CD30 expressing lymphoma cutaneous involvement were recruited into 3 cohorts: 1.5...
<h3>Background</h3> Despite objective responses to PARP inhibition and improvements in progression-free survival compared standard chemotherapy patients with BRCA-associated triple-negative breast cancer (TNBC), benefits are transitory. <h3>Methods</h3> Using high dimensional single-cell profiling of human TNBC, here we demonstrate that macrophages the predominant infiltrating immune cell type TNBC. Through multi-omics show inhibitors enhance both anti- pro-tumor features through glucose...
<p>Figure S1. REMARK diagram Figure S2. NanoString Tumor Inflammation Signature by breast cancer intrinsic subtype S3. individual gene expression changes cohort Table Pre-treatment immune microenvironment and response to preoperative therapy Tissue-based biomarkers in patients with pathologic complete References for classification of genes as M1-like or M2-like</p>
<p>Figure S1. REMARK diagram Figure S2. NanoString Tumor Inflammation Signature by breast cancer intrinsic subtype S3. individual gene expression changes cohort Table Pre-treatment immune microenvironment and response to preoperative therapy Tissue-based biomarkers in patients with pathologic complete References for classification of genes as M1-like or M2-like</p>
<div>AbstractPurpose:<p>Hormone receptor–positive/HER2-negative (HR<sup>+</sup>/HER2<sup>−</sup>) breast cancer is associated with low levels of stromal tumor-infiltrating lymphocytes (sTIL) and PD-L1, demonstrates poor responses to checkpoint inhibitor therapy. Evaluating the effect standard chemotherapy on immune microenvironment may suggest new opportunities for immunotherapy-based approaches treating...